Literature DB >> 25369343

Three-dimensional reconstruction of the S885A mutant of human mitochondrial Lon protease.

S Kereïche1, L Kováčik1, V Pevala2, L Ambro2, J Bellová2, E Kutejová2, I Raška1.   

Abstract

The Lon protein is a protease belonging to the superfamily of ATPases associated with diverse cellular activities (AAA+). Its main function is the control of protein quality and the maintenance of proteostasis by degradation of misfolded and damaged proteins, which occur in response to numerous stress conditions. It also participates in the regulation of levels of transcription factors that control pathogenesis, development and stress response. We focus our interest on the structure of human mitochondrial Lon (hLon) protease, whose altered expression levels are linked to some severe diseases such as epilepsy, myopathy, or lateral sclerosis. We present the first 3D structure of the ADP-bound human Lon S885A mutant obtained by electron microscopy as a result of preliminary negative staining studies. S885A appears as a hexameric ring of 120 Å diameter having 90 Å in height. Its resolution was estimated at 19 Å by the FSC = 0.5 criterion. This model is a primary step towards the understanding of the mechanism of action of the Lon protease and its involvement in the pathogenesis development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25369343

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  2 in total

1.  The N-terminal domain plays a crucial role in the structure of a full-length human mitochondrial Lon protease.

Authors:  Sami Kereïche; Lubomír Kováčik; Jan Bednár; Vladimír Pevala; Nina Kunová; Gabriela Ondrovičová; Jacob Bauer; Ľuboš Ambro; Jana Bellová; Eva Kutejová; Ivan Raška
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

2.  Identification of HSPA8 as a candidate biomarker for endometrial carcinoma by using iTRAQ-based proteomic analysis.

Authors:  Nianchun Shan; Wei Zhou; Shufen Zhang; Yu Zhang
Journal:  Onco Targets Ther       Date:  2016-04-13       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.